Braingrade | Peter Schlecht, CEO

(Transcription)

Peter Schlecht  0:00  

Thank you very much for the introduction. I personally believe improving the human brain. giving it an upgrade is the most important thing, what we can do with our lives. And I'm happy to present you today, the first specialized brain implant for Alzheimer's patients. I don't have to educate you about the challenge. Alone in the US 6 million people have currently Alzheimer's, one out of three elder patients die with it. These are more than breast cancer and prostate cancer combined cases. And it is it's increasing fast, and COVID will have to its bad on it on top of it. So the problem we are facing today is still that we have nothing to cure, and no effective treatment for this disease. So we have nothing to stop the decline for the patient in any way. Today, if you got diagnosed with mild cognitive impairment, you have an average, three to four years, until to a severe decline with brain grade, and this is the one thing you should take from my presentation, we have the opportunity to give the families and the patients over a decade on top of it. For that, we are building the first specialized brain implant for Alzheimer's. It's a fully implantable neurostimulator to record and stimulate the neurons in the depth of the human brain. It's exactly the device that physicians and scientists are asking for so long. Currently, we are in the prototype stage. So how will the results with our device look like? Well, today with no treatment, for severe decline, the fast decline only a little bit slower, kind of with some truck treatments, we will give the patient kind of bump in memory, and we will dramatically slow down the progress of the disease. How do we do that? First we stimulate in the hippocampus and in the internal cortex. Second, we're stimulating in the nucleus basadas of mainnet. Four, the hippocampus and the internal cortex. We are following our lead scientist, Professor Hanson, who is at Wake Forest has work in this area for the last three decades. There are multiple animal studies and there are also multiple and many in human studies that have shown results. But to summarize them, we see a decrease in amyloid beta plaques, we see a promotion of neurogenesis and most important for the patient because he feels the outcome is that we can improve the human memory this affects three the second part what we are doing is a stimulation in the nucleus in masalas of mainnet. So, we are tapping into the columnar check center of the human brain 128 animal studies solid results from the field over the last 20 years showing good outcomes and they are multiple in human studies, also over multiple years. And we are working together for our first study together with the main center for the key studies you see here. So to summarize the result out of that is we are restoring cholinergic tone. We have preservation of cholinergic neurons, we even kind of kickstart or kind of kick back in place the glucose metabolism. And very important for the patient again is that we decrease this cognitive decline and we improve the memory performance. The left side you see out comes over two years on the right side, it's a result of the 10 weeks of stimulation. This is what the patient was capable of doing. He couldn't even draw a circle. So he had severe Alzheimer's, with 10 weeks of simulation, this is the result, we were finding. It was him so far, that he could remember again, the names of his children during the simulation, what he couldn't do before. I think these are spectacular results, what we should all be made available for all Alzheimer patients. We have a team of the world's leading brain computer interface companies, and neuro Tech Research Centers together from co founders and their executives. We have an exceptional Scientific Advisory Board. And you don't even see everyone here. And we have a new research report, talking about neurosurgeons what has changed and why now is the time to bring such a device to the market is that they say implementation is solved. It's through reduction of operational risk and time through robotic support and improvement of trajectory planning and navigation and the brain thinks you know, we just have today better technology, better access to data and AI, we have a new way of how we can produce. And we have a new way kinda and breakthroughs in material. We also understand the brain better, and we are finally going away kind of from only the amyloid better hypothesis for Alzheimer disease. We even have earlier detection. So there is more to preserve. And we have a way better patient selection. Because one thing everyone knows about Alzheimer's, that Alzheimer trials are failing. And when we actually look deeper into the cohorts, we figure out that that's not true for all fields. That's mainly for tracks but not so much for by electronics. And now then we have to ask us, Why are there specialized devices for all the other kind of cases, but not for Alzheimer's. And one reason for that is that so far, we could reach and made these trials with devices who has been built for Parkinson's disease. But just to tell you one thing, they have been built for exactly the opposite for suppressing brain states and not for enhancing them. So what makes us different is that we have a network approach. Every Pupil student learns it's the memory network. Obviously, you need a network approach, we have special probes and electrodes, because until today and recently a few years, you have always had to decide if you have a high resolution with the electrodes in the brain. He said the probes that come into the brain at the tip of electrodes or you have longevity, but through the help and with the materials silicon carbide, we can combine that after the lead from Felix Tico has been the former director of micro fabrication at Neural Link. On the other side, the other 50% of the software and the explosion of data we will generate with kind of the increase of electrodes and kind of massively increased amount of record capabilities of our device. Plus, we will close the loop for the data, we will close it on the electrophysiological side. So improve the treatment for every patient, but also kind of with the patient on how he is behaving. This is lead led by Robert etching, the former co founder of petromax. Our team we have built up on STEM Ulation patterns, what we have and what have been named by nature as the future of deep brain stimulation.We have done a first inhuman proof of concept. And we are now preparing. I know you can read this instantly. For our first clinical study. What we'll start still in q1 So the market and the opportunity here is massive. And I think this is also the right timing for you to invest because the last good news for Alzheimer's had a massive increase in valuation. And it stays and will become a $2.8 trillion problem means makes like a serviceable obtainable market of 111 billion. And I haven't talked about all the other neurological diseases that device could be used for. So it is the most expensive disease in the United States and we can do something against it. Today, we've already raised precede from exceptional investors like AI X ventures and Mindfocus VC. Today, we are raising our seed round. We want bring further clinical validation with this money, and we will have the embodiment of the device. So we'll have the major de risking steps done with that and curate the data pipelines. Then we will go for a Series A for the design freeze and start feasibility trial. Please join that we could have give this lady what is my grandmother, another decade. And I hope you join us on this journey. Thank you very much and please get in contact